{"id":4660,"date":"2025-03-31T18:12:15","date_gmt":"2025-03-31T18:12:15","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/rifampicin-txt\/"},"modified":"2025-03-31T18:12:15","modified_gmt":"2025-03-31T18:12:15","slug":"rifampicin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/rifampicin-txt\/","title":{"rendered":"rifampicin.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAntibacterial agent:Tuberculosis Staphylococcal infection

DOSE IN NORMAL RENAL FUNCTION <\/H3>600\u20131200 mg daily in 2\u20134 divided doses

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :822.9<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :80<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 15\u201330<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.64\u20130.66<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20135\/1.8\u201311

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 50% \u2013 100% of normal dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: metabolism of disopyramide, mexiletine and propafenone accelerated\n
  • Antibacterials: reduced concentration of chloramphenicol, clarithromycin, dapsone, trimethoprim and telithromycin \u2013 avoid with telithromycin; monitor LFTs in combination with quinupristin\/dalfopristin; concentration increased by clarithromycin and other macrolides\n
  • Anticoagulants: reduced anticoagulant effect of coumarinsAntidiabetics: reduced antidiabetic effect of chlorpropamide and tolbutamide; concentration of rosiglitazone, nateglinide and repaglinide reduced \u2013 may need to increase dose of rosiglitazone; possibly reduced antidiabetic effect with sulphonylureas\n
  • Anti-epileptics: reduced concentration of phenytoin and lamotrigine\n
  • Antifungals: concentration of both drugs may be reduced with ketoconazole; reduced concentration of fluconazole, itraconazole, posaconazole and terbinafine; concentration of voriconazole reduced \u2013 avoid concomitant use; initially increases then reduces caspofungin concentration\n
  • Antipsychotics: reduced concentration of haloperidol, aripiprazole and clozapine \u2013 increase dose of aripiprazole\n
  • Antivirals: concentration of abacavir and tipranavir possibly reduced \u2013 avoid with tipranavir; concentration of amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, nevirapine and saquinavir reduced \u2013 avoid; concentration of efavirenz reduced \u2013 increase dose of efavirenz; avoid with zidovudineAtovaquone: concentration of atovaquone reduced (possible therapeutic failure of atovaquone)Bosentan: reduced bosentan concentration \u2013 avoid\n
  • Calcium-channel blockers: metabolism of diltiazem, verapamil, isradipine, nicardipine, nifedipine, nisoldipine and nimodipine accelerated\n
  • Ciclosporin: markedly reduced levels (danger of transplant rejection); ciclosporin dose may need increasing 5-fold or moreCorticosteroids: reduced level of corticosteroids \u2013 double steroid dose. Give as twice daily dosageCytotoxics: reduced concentration of erlotinib, sunitinib, dasatinib and imatinib \u2013 avoid with imatinib\n
  • Diuretics: concentration of eplerenone reduced \u2013 avoidOestrogens and progestogens: reduced contraceptive effect due to increased metabolism\n
  • Tacrolimus: reduced tacrolimus concentrationSirolimus: reduced sirolimus concentration.646 riFAMPiCin

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Use solvent provided

    Route <\/H4>Oral, IV

    Rate of Administration <\/H4>2\u20133 hours

    Comments<\/H4>Dilute in 500 mL glucose 5% or sodium chloride 0.9%For central administration, 600 mg in 100 mL glucose 5% over 0.5\u20132 hours has been used (unlicensed). Stable for up to 24 hours at room temperature

    OTHER INFORMATION <\/H4>Some units give dose in concentrations up to 60 mg\/mL (in its own solvent) over 10 minutes, on prescriber\u2019s responsibilityMay cause acute interstitial nephritis, potassium wasting or renal tubular defectsReduce dose if LFTs are abnormal or patient <45 kgAbsorption from gastrointestinal tract can be reduced by up to 80% by the presence of food in the gastrointestinal tract
    CAPD exit site infections: 300 mg twice daily for 4 weeks has been usedRifampicin is excreted into
    CAPD fluid causing an orange\/yellow colourMonitor rifampicin levels if necessary In severe renal impairment there is no increase in half-life at doses less than 600 mg daily.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antibacterial agent:Tuberculosis Staphylococcal infection DOSE IN NORMAL RENAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4660","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4660"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4660\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}